Jump to ContentJump to Main Navigation

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Editorial Board Member: Gillery, Philippe / Kazmierczak, Steven / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Schlattmann, Peter / Whitfield, John B.

12 Issues per year

IMPACT FACTOR 2013: 2.955
Rank 5 out of 29 in category Medical Laboratory Technology in the 2013 Thomson Reuters Journal Citation Report/Science Edition



Genetic variability of the fructosamine 3-kinase gene in diabetic patients

Lorena Mosca1, 3 / Silvana Penco1 / Maria C. Patrosso1 / Alessandro Marocchi1 / Annunziata Lapolla2 / Giovanni Sartore2 / Nino C. Chilelli2 / Renata Paleari3 / 3

1Laboratorio di Genetica Medica, Ospedale Niguarda Ca’ Granda, Milano, Italy

2Dipartimento di Scienze Mediche e Chirurgiche, Università degli Studi di Padova, Padova, Italy

3Dipartimento di Scienze e Tecnologie Biomediche, Università degli Studi di Milano, Milano, Italy

Corresponding author: Andrea Mosca, Dip. Scienze e Tecnologie Biomediche, Via Fratelli Cervi 93, 20090 Segrate, Milano Phone: +39 02 5033 0422, Fax +39 02 9998 7559

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 49, Issue 5, Pages 803–808, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2011.133, February 2011

Publication History

Published Online:


Background: Nonenzymatic glycation appears to be an important factor in the pathogenesis of diabetic complications. Fructosamine 3-kinase (FN3K), initially identified in erythrocytes, appears to be responsible for the removal of fructosamine from proteins, suggesting a protective role in nonenzymatic glycation. Recently, genetic variants in the FN3K gene have been studied in diabetic patients. The aim of our study was the molecular characterization of the FN3K gene in a representative group of Italian patients with type 1 (T1DM) and 2 (T2DM) diabetes mellitus and in a cohort of healthy controls.

Methods: Seventy diabetic subjects (35 type 1 and 35 type 2) with stable glycemic control and 33 healthy control subjects were evaluated using PCR and direct sequencing of the FN3K gene. Denaturing high performance liquid chromatography (DHPLC) was used in controls for screening for the presence of the genetic variants previously found in diabetic patients.

Results: Seven different genetic variants were identified, five of them already reported and two new: the p.R187X and p.Y239C mutations identified in two females affected by T2DM. No significant association was found between certain polymorphisms and diabetes conditions. Preliminary haplotype studies are also reported. With respect to genotypes, we noted that some were not present in all the investigated cohort, and some were found related to higher glycated hemoglobin compared to others, although not at a significant level, probably because of the small number of subjects investigated.

Conclusions: In conclusion, this study identified two new mutations and additional variants within the FN3K gene. This is the first study on FN3K in Italy. Future work is needed to achieve a better understanding of the FN3K enzyme and its possible clinical utility in the management of diabetic patients.

Keywords: diabetes; fructosamine 3-kinase (FN3K); glycated hemoglobin; mutation analysis

Comments (0)

Please log in or register to comment.
Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.